CompletedNCT00520507
Sleep and cognitive effects of olanzapine for bipolarity-related depression
About this title
Read the official source — NCT00520507Medication studyAges 18+Canada
Understand this study
Who was this study for?
Listed age limits: from 18 years.
What did participation involve?
Depending on the group, the protocol specifies the study medication (olanzapine) or a placebo (an inactive comparison treatment).
- Listed locations
- KingstonSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 27
- Sponsor
- Queen's University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Canada
- Age range
- Over 18 Years
- Official registry ID
- NCT00520507
- Official title
Show the full official title
An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedKingston
Questions about this study
Who is behind this study?
The study sponsor is Queen's University, a university.
Did this study involve medication?
Yes. The study involved medication, including Olanzapine and Placebo.
Who was this study for?
Listed age limits: from 18 years.
